The object of the study is to compare the treatment effect of bevacizumab (Avastin), an
antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy
(PDT) for patients with neovascular age-related macular degeneration, the leading cause of
vision severe loss in the Western world.